Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New knee cartilage implant tested in first human study

NCT ID NCT07249489

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 6 times

Summary

This early study tests a new implant called the Nanochon Chondrograft for repairing cartilage lesions in the knee. It involves 10 adults aged 22 to 60 and aims to check if the implant is safe. The main focus is on avoiding serious side effects over one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female ≥22 years and ≤ 60 years of age * MRI knee evaluation completed within 6 months prior to enrollment * Participant must be able to read and speak English * Participant must voluntarily sign the REB approved informed consent form (ICF) Exclusion Criteria: * Any known systemic cartilage and/or bone disorder, such as, but not limited to, osteoporosis, chondrodysplasia or osteogenesis imperfecta * Requires bilateral knee surgery * Pregnancy, planning to become pregnant or breast feeding * Any significant illness (metastasis cancer of any type) that decreases the probability of the participant's survival to 12 months * Known insulin dependent diabetes mellitus * Steroid treatment (oral or IV) within the past 6 months * Participant is: 1. receiving workman's compensation 2. receiving prescription narcotic medication 3. active with litigation relating to musculoskeletal injuries or disorders 4. a prisoner or pending incarceration * Comorbidities that could impact study participation or results (e.g., autoimmune disorder, HIV, neuropathic pain or fibromyalgia, restless leg syndrome, active infection, or pain requiring chronic pain management), in the opinion of the investigator at the time of enrollment * Significant psychiatric disorders (e.g., major depression, anxiety disorders, bipolar disorder, and schizophrenia) * Substance and/or alcohol dependence and/or abuse based on clinical history, physical exam and participant presentation * Current participation in another drug or device study that, in the opinion of the investigator at the time of enrollment, would interfere with participation in this study * Participant has claustrophobia or implanted metallic devices (e.g., cardiac pacemakers, insulin pumps, nerve stimulators), medically implanted clips or other electronically, magnetically or mechanically activated implants that would contraindicate undergoing an MRI * Known allergy or hypersensitivity to any investigational device materials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee cartilage lesions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    2 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Orthopaedic Clinic

    Toronto, Ontario, Canada

    Contact Email: •••••@•••••

  • University of British Columbia

    Vancouver, British Columbia, V6T 1Z4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.